Last week, uniQure achieved a breakthrough in developing disease-modifying therapies for Huntington’s Disease by showing that AMT-130 slowe...

Yesterday was a memorable day in the development of drugs for two of the main severe monogenic diseases without treatments to change disease...

Many industry insiders expected Sarepta CEO Doug Ingram to be out by now.  Instead, a new dynamic is gathering steam: Vinay Prasad, the rece...

  Last night, news broke that pharma giant Eli Lilly was in talks to acquire Verve Therapeutics.   After a 3-year lull in major CRISPR deal...

When Intellia Therapeutics set out to develop a CRISPR-based prekallikrein knockout for hereditary angioedema (HAE), it was as a compelling ...

There is now overwhelming evidence that the new US healthcare administration is serious in its mission of making its citizens inherently hea...

Prime editing researchers are so excited about the technology that sponsor Prime Medicine is unable to control the newsflow on their CGD tri...